



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund

**Medicines Recommended by NICE and AWMSG:
Health Board Formulary Status
(From 1 January 2017 to 30 June 2018)**

EXECUTIVE SUMMARY

Of the 110 medicines within the New Treatment Fund which were recommended more than 60 days ago, all health boards had at least 94% of these medicines on formulary within 60 days.

Of the 110 medicines within the New Treatment Fund which were recommended more than 60 days ago, an average of 13 days was taken to add these to formularies.

Of the 17 medicines within the New Treatment Fund which were recommended within the last 60 days, six health boards had at least 88% of these medicines on formulary.

Of the 127 medicines within the New Treatment Fund, six health boards had at least 98% of these medicines on formulary.

BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All data in this report is as of 30 June 2018.

SOURCE OF INFORMATION

Across Wales, six of the seven health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Abertawe Bro Morgannwg University Health Board (UHB) and Velindre NHS Trust (Velindre Cancer Centre) have separate formulary systems. Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

Table 1. Formulary status and time elapsed since latest AWMSG/NICE recommendation for New Treatment Fund medicines (30 June 2018)

Appraisal Approval Date*	CAA Available Date ^v	AWMSG or NICE ref	Previous AWMSG ref	Medicine name	Abbreviated indication	Health Board formulary status ^{A#}						
						ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
11/01/17		TA427	2590	Pomalidomide	Multiple myeloma	-	-	1	-	-	30	78
11/01/17		TA428		Pembrolizumab	Lung cancer (previously treated)	1	-	1	65	100	27	78
25/01/17		TA429		Ibrutinib	Leukaemia	1	-	1	50	51	1	64
25/01/17		TA430	2417	Sofosbuvir/velpatasvir	Hepatitis C	-	-	1	-	51	1	-
25/01/17		TA431		Mepolizumab	Asthma	1	-	1	68	51	13	64
07/02/17		ID758 (HST6)		Asfotase alfa	Hypophosphatasia	0	153	30	0	149	2	156
22/02/17		HST4		Migalastat	Fabry disease	0	40	30	0	41	135	140
22/02/17		TA432		Everolimus	Renal cancer	-	0	1	-	-	-	69
22/02/17		TA433		Apremilast	Psoriatic arthritis	-	-	1	-	23	20	-
02/03/17		ID785 (TA443)		Obeticholic acid	Biliary cirrhosis	56	-	64	117	57	20	53
02/03/17		ID794 (TA439)	2407	Cetuximab	Colorectal cancer	20	1	-	-	-	55	53
02/03/17		ID794 (TA439)	2744	Panitumumab	Colorectal cancer	27	-	1	50	57	55	53
10/03/17		ID904 (TA442)		Ixekizumab	Psoriasis	1	-	56	91	49	12	45
14/03/17		1586		Aflibercept (Eylea®)	Myopic choroidal neovascularisation	1	-	0	-	-	1	49
14/03/17		1658		Triptorelin	Prostate cancer	-	-	1	-	38	1	-
15/03/17		ID827 (TA441)		Daclizumab	Multiple sclerosis	42	-	1	-	44	7	-
03/04/17		2597		Idelalisib	Follicular lymphoma	1	-	0	-	39	29	29
13/04/17		ID579 (TA445)		Secukinumab	Psoriatic arthritis	11	-	1	-	19	19	11
13/04/17		ID579 (TA445)	1713	Certolizumab pegol	Psoriatic arthritis	-	-	1	-	-	19	-
27/04/17		ID843 (TA456)		Ustekinumab	Crohn's disease	1	7	34	-	40	43	7
27/04/17		ID804 (TA450)	589	Blinatumomab	Leukaemia	-	-	-	-	40	43	7
28/04/17		ID722 (TA446)	1255	Brentuximab	Hodgkin lymphoma	-	-	-	-	-	4	42
28/04/17		ID671 (TA451)	1163	Ponatinib	Leukaemia	-	-	-	-	-	42	6
12/05/17		ID858 (TA449)	390	Sunitinib	Neuroendocrine tumours	-	0	-	-	-	28	28
12/05/17		ID858 (TA449)	142	Everolimus	Neuroendocrine tumours	-	0	19	-	-	28	28
19/05/17		ID908 (TA448)		Etelcalcetide	Hyperparathyroidism	1	5	12	46	17	49	21
31/05/17		ID709 (HST5)		Eliglustat	Gaucher disease	0	40	37	0	6	37	37
31/05/17	28/07/17	ID990 (TA447)		Pembrolizumab	Lung cancer (previously untreated)	60	10	37	64	0	-	10
02/06/17		ID763 (TA460)		Adalimumab	Uveitis	-	19	18	-	28	19	-
02/06/17		ID763 (TA460)		Dexamethasone	Uveitis	-	14	-	-	28	19	-
02/06/17		ID972 (TA462)		Nivolumab	Hodgkin lymphoma	0	6	18	-	28	19	1
09/06/17		ID837 (TA504)		Pirfenidone	Idiopathic pulmonary fibrosis	-	3	11	-	-	12	-
09/06/17		ID934 (TA457)		Carfilzomib	Multiple myeloma	4	10	10	41	13	12	1
09/06/17	23/06/17	ID959 (TA465)		Olaratumab	Sarcoma	25	3	11	24	0	12	1
09/06/17		ID854 (TA455)		Etanercept	Plaque psoriasis	-	33	11	-	20	12	-
09/06/17		ID854 (TA455)	2068	Ustekinumab	Plaque psoriasis	-	33	11	-	20	12	-

Appraisal Approval Date*	CAA Available Date ^v	AWMSG or NICE ref	Previous AWMSG ref	Medicine name	Abbreviated indication	Health Board formulary status ^{^#}						
						ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
09/06/17		ID854 (TA455)	2571	Adalimumab	Plaque psoriasis	-	33	11	-	20	12	-
15/06/17	19/06/17	ID1013 (TA458)		Trastuzumab emtansine	Breast cancer	6	4	11	18	4	6	1
22/06/17		ID984 (TA461)		Roflumilast	Chronic obstructive pulmonary disease	0	7	2	56	4	8	1
22/06/17		ID621 (TA459)	930	Collagenase clostridium histolyticum	Dupuytren's contracture	-	7	-	-	-	-	1
29/06/17		ID979 (TA466)		Baricitinib	Rheumatoid arthritis	5	1	5	50	1	8	1
07/07/17		ID899 (TA467)		Holoclar	Eye burns	40	31	6	48	7	45	42
10/07/17		ID931 (TA463)		Cabozantinib	Renal cancer	0	2	1	-	2	31	-
10/07/17		ID782 (TA464)		Alendronic acid (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Ibandronic acid (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Risedronate sodium (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Ibandronic acid (IV)	Osteoporosis	-	0	8	-	-	-	-
10/07/17		ID782 (TA464)		Zoledronic acid (IV)	Osteoporosis	-	0	33	-	-	-	-
12/07/17		3435		Aviptadil phenolamine	Erectile dysfunction	0	6	14	36	6	31	37
20/07/17		ID872 (TA479)		Reslizumab	Asthma	16	11	12	28	8	50	29
26/07/17		ID841 (TA472)		Obinutuzumab	Follicular lymphoma	14	16	4	23	2	26	23
27/07/17		ID870 (TA471)		Eluxadoline	Irritable bowel syndrome	0	11	4	22	22	20	22
04/08/17		ID776 (TA475)		Dimethyl fumarate	Psoriasis	-	7	4	20	14	13	13
04/08/17		ID1058 (TA476)	1999	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer	-	0	4	-	14	-	13
07/08/17		3371		Adalimumab	Acne inversa	-	4	4	-	11	10	-
07/08/17		2224		Cefuroxime	Eye inflammation	-	4	11	46	-	-	11
07/08/17		2527		Triamcinolone hexacetonide	Juvenile idiopathic arthritis	-	4	1	46	11	10	11
08/08/17		ID1016 (TA473)		Cetuximab	Head and neck cancer	0	3	3	-	10	1	-
10/08/17		ID1012 (TA474)	284	Sorafenib	Liver cancer	0	0	3	-	-	-	8
24/08/17		ID512 (TA478)		Brentuximab vedotin	Lymphoma	0	7	7	-	11	-	15
07/09/17		ID456(TA481), ID346 (TA482)		Basiliximab	Kidney transplant	-	0	27	-	-	-	-
07/09/17		ID456(TA481), ID346 (TA482)		Tacrolimus (immediate release)	Kidney transplant	-	0	27	-	-	-	-
07/09/17		ID456(TA481), ID346 (TA482)		Mycophenolate mofetil	Kidney transplant	-	0	27	-	-	-	-
08/09/17		ID526 (TA480)		Tofacitinib	Rheumatoid arthritis	0	3	26	41	3	47	28
20/09/17	09/10/17	ID900 (TA484)		Nivolumab	Lung cancer (non-squamous)	46	0	13	-	0	16	-
20/09/17	09/10/17	ID811 (TA483)		Nivolumab	Lung cancer (squamous)	46	0	13	-	0	16	-
22/09/17		ID952 (TA486)	1586	Aflibercept	Myopic choroidal neovascularisation	-	0	10	-	-	0	-
22/09/17	04/10/17	ID994 (TA485)		Sarilumab	Rheumatoid arthritis	12	5	10	37	0	20	14
28/09/17	27/10/17	ID884 (TA491)		Ibrutinib	Waldenstrom's macroglobinaemia	0	4	5	42	0	8	-
05/10/17	27/10/17	ID944 (TA487)		Venetoclax	Leukaemia	22	7	4	42	0	14	12
10/10/17		2680		Ivacaftor	Cystic fibrosis	0	27	24	-	3	31	-

Appraisal Approval Date*	CAA Available Date [†]	AWMSG or NICE ref	Previous AWMSG ref	Medicine name	Abbreviated indication	Health Board formulary status ^{^#}						
						ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
12/10/17		ID1056 (TA488)	1018	Regorafenib	Gastrointestinal stromal tumours (sarcoma)	-	14	-	-	1	0	27
13/10/17		ID971 (TA490)		Nivolumab	Head and neck cancer (squamous)	22	5	21	0	5	28	-
17/10/17		3282		Desmopressin	Nocturia	0	8	17	41	22	24	-
19/10/17		3372		5-aminolaevulinic acid	Skin cancer	0	6	17	-	20	22	26
19/10/17		3295		C1 inhibitor	Angioedema	0	6	17	-	-	0	-
19/10/17		3373		Dolutegravir	HIV	0	6	17	-	-	22	20
19/10/17		3007	3007	Glecaprevir/pibrentasvir	Hepatitis C	0	29	22	28	20	22	20
19/10/17		976		Lenvatinib	Thyroid cancer	0	6	17	4	20	22	-
19/10/17		3436		Tiotropium	Asthma	0	4	17	-	20	0	20
01/11/17		ID939 (TA492)		Atezolizumab	Urothelial cancer	0	8	9	23	7	9	7
03/11/17		ID64 (TA493)		Cladribine	Multiple sclerosis	0	3	0	35	5	7	6
16/11/17		ID1026 (TA496)		Ribociclib	Breast cancer	0	6	25	22	1	12	26
16/11/17		ID915 (TA495)		Palbociclib	Breast cancer	0	6	25	13	1	12	26
16/11/17		ID903 (TA497)		Golimumab	Arthritis	0	0	25	-	-	25	0
28/11/17		3545		Pegvisomant	Acromegaly	0	3	13	51	6	36	14
28/11/17		3468		Stiripentol	Epilepsy	0	3	13	-	6	13	14
07/12/17		ID1085 (TA499)		Glecaprevir/pibrentasvir	Hepatitis C	0	0	1	-	-	0	0
07/12/17		ID1117 (TA500)		Ceritinib	Lung cancer	1	6	4	43	1	26	29
08/12/17		3035		Adalimumab	Eye inflammation	0	21	3	41	7	3	0
08/12/17		ID1029 (TA498)		Lenvatinib	Renal cancer	5	6	21	41	4	25	28
14/12/17	14/12/17	ID753 (TA502)		Ibrutinib	Lymphoma	4	1	15	35	5	1	56
19/12/17	12/01/18	ID807 (TA505)		Ixazomib	Multiple Myeloma	0	0	-14	34	4	4	27
17/01/18	09/02/18	ID953 (TA510)		Daratumumab	Multiple Myeloma	-3	0	-1	34	46	4	27
18/01/18	16/03/18	ID1055 (TA507)		Sofosbuvir/velpatasvir/voxilaprevir	Hepatitis C	0	0	-36	34	31	11	20
01/02/18	01/02/18	ID523 (TA509)		Pertuzumab	Breast cancer	0	0	7	29	1	4	7
09/02/18		ID1020 (TA513)		Obinutuzumab	Lymphoma	0	0	27	34	3	27	27
09/02/18		ID878 (TA511)		Brodalumab	Psoriasis	-	0	27	34	17	27	27
12/02/18		ID591 (TA512)		Tivozanib	Renal cancer	2	3	24	56	14	24	24
15/02/18		ID56 (TA516)	577	Cabozantinib	Thyroid cancer	0	0	-	0	-	21	26
01/03/18	19/03/18	ID1102 (TA517)		Avelumab	Merkel cell cancer	0	1	-11	31	7	8	10
05/03/18		3557		Lopinavir/ritonavir	HIV	-	3	-	0	-	3	24
05/03/18		3343		Lacosamide	Epilepsy	-	3	-	0	-	3	24
05/03/18		2418		Symtuza	HIV	0	3	3	45	4	3	24
08/03/18		ID1051 (TA518)		Tocilizumab	Arteritis	0	0	0	42	1	19	21
16/03/18	16/03/18	ID1019 (TA519)		Pembrolizumab	Urothelial cancer	0	4	3	59	10	11	20
22/03/18		3397		Levodopa-carbidopa intestinal gel	Parkinson's disease	3	14	7	28	-	6	21

Appraisal Approval Date*	CAA Available Date [‡]	AWMSG or NICE ref	Previous AWMSG ref	Medicine name	Abbreviated indication	Health Board formulary status ^{^#}						
						ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
22/03/18		3627		Misoprostol	Induction of labour	0	14	7	0	5	7	21
09/04/18		ID970 (TA520)		Atezolizumab	Lung cancer	0	3	8	38	7	16	3
27/04/18	27/04/18	ID1209 (TA522)		Pembrolizumab	Urothelial cancer	0	3	3	55	3	3	3
03/05/18		ID1075 (TA521)		Guselkimag	Psoriasis	0	0	0	49	5	26	6
04/05/18		ID894 (TA523)		Midostaurin	Leukaemia	4	7	0	48	12	25	6
04/05/18		ID446 (TA526)		Arsenic trioxide	Leukaemia	0	0	-	0	-	-	6
04/05/18		ID1366 (TA524)	1255	Brentuximab vedotin	Lymphoma	-	-	0	0	-	25	6
14/05/18		ID809	1510	Interferon beta 1a	Multiple sclerosis	-	11	-	0	2	-	11
14/05/18		ID809		Interferon beta 1b (Extavia)	Multiple sclerosis	-	3	3	0	2	-	11
14/05/18		ID809		Glatiramer acetate	Multiple sclerosis	-	3	3	0	2	-	11
17/05/18		ID1327 (TA525)		Atezolizumab	Urothelial cancer	0	0	0	39	1	12	8
01/06/18	01/06/18	ID1041		Niraparib	Ovarian cancer	0	0	3	25	7	20	19
06/06/18	06/06/18	ID1349		Pembrolizumab	Lung cancer	-	-	-	0	-	-	14
13/06/18		3293		Icatibant acetate	Angioedema	0	1	0	17	5	8	7
13/06/18		3233		Ranibizumab	Visual impairment	0	1	0	17	5	8	7
13/06/18		700		Selexipag	Hypertension	0	1	0	17	5	8	7
22/06/18		ID937		Ocrelizumab	Multiple sclerosis	0	7	4	8	3	4	4
22/06/18		ID1048		Dupilumab	Dermatitis	0	7	4	8	8	4	4
28/06/18		ID925		Alectinib	Lung cancer	2	2	2	2	1	2	2
29/06/18		ID1194		Ixekizumab	Arthritis	1	1	1	1	1	1	1

* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

^ Number of days from latest AWMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is "already on formulary" but for a different indication. However this is not always the case.

The determination of formulary status is considered as the availability of the medicine to treat patients.






‡ CAA (Commercial Access Agreement) Available Date information is provided by the all Wales Medicines Procurement Specialist Pharmacist

Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[']' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 30 June 2018.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 30 June 2018.
		Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 30 June 2018. '-' indicates CAA is not yet available.

Table 2. Velindre Cancer Centre medicines status

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status					
					C+V	Powys*	ABMU*	Cwm Taf	ABUHB	VCC ONLY
11/01/2017		TA428	Pembrolizumab 2 nd line	Lung cancer	**	100	100	100	100	100
22/02/2017		TA432	Everolimus	Renal cancer	-	-	-	-	-	-
02/03/2017		ID794	Cetuximab	Colorectal cancer	-	-	-	-	-	-
02/03/2017		ID794	Panitumumab	Colorectal cancer	50	50	50	50	50	50
14/03/2017		1658	Triptorelin	Prostate cancer	38	38	38	38	38	38
12/05/2017		ID858	Everolimus	Neuroendocrine tumours	0	0	0	0	0	0
12/05/2017		ID858	Sunitinib	Neuroendocrine tumours	0	0	0	0	0	0
31/05/2017	28/07/2017	ID990	Pembrolizumab 1 st line	Lung cancer	**	1	1	1	1	1
09/06/2017	23/06/2017	ID959	Olaratumab	Sarcoma	4	4	4	4	4	4
15/06/2017	19/06/2017	ID1013	Trastuzumab Emtansine	Breast	6	6	6	6	6	6
10/07/2017		ID931 (TA463)	Cabozantinib	Renal cancer	0	0	0	0	0	0
04/08/2017		ID1058	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer	0	0	0	0	0	0
08/08/2017		ID1016	Cetuximab	Head and neck cancer	10	10	10	10	10	10
10/08/2017		ID1012	Sorafenib	Liver cancer	0	0	0	0	0	0
20/09/2017	09/10/2017	ID900	Nivolumab	Lung cancer (non-squamous)	**	0	0	0	0	0
20/09/2017	09/10/2017	ID811	Nivolumab	Lung cancer (squamous)	**	0	0	0	0	0
13/10/2017		ID971	Nivolumab	Head and neck cancer (squamous)	0	0	0	0	0	0
01/11/2017		ID939	Atezolizumab	Urothelial cancer	24	24	24	24	24	24
19/10/2017		976	Lenvatinib	Thyroid cancer	4	4	4	4	4	4
16/11/2017		ID1026	Ribociclib	Breast cancer	21	21	21	21	21	21
16/11/2017		ID915	Palbociclib	Breast cancer	13	13	13	13	13	13
07/12/2017		ID1117	Ceritinib	Lung cancer	**	13	13	13	13	13
08/12/2017		ID1029 (TA498)	Levatinib	Renal Cell Carcinoma	54	54	54	54	54	54
01/02/2018		ID523	Pertuzumab	Breast cancer	29	29	29	29	29	29
12/02/2018		ID591	Tivozanib	Renal cancer	56	56	56	56	56	56
15/02/2018		ID56	Cabozantinib	Thyroid cancer	0	0	0	0	0	0
01/03/2018	19/03/2018	ID1102	Avelumab	Merkel Cell	51	51	51	51	51	51
16/03/2018	16/03/2018	ID1019	Pembrolizumab	Urothelial cancer 2 nd line	46	46	46	46	46	46
09/04/2018		ID970	Atezolizumab 2 nd line	Lung Cancer	**	32	32	32	32	32
27/04/2018		ID1209	Pembrolizumab	Urothelial cancer – platinum illegible	59	59	59	59	59	59
17/05/2018		ID1327	Atezolizumab	Urothelial cancer-	39	39	39	39	39	39
31/05/2018		ID1098	Crizotinib	Lung Cancer ROS1+	-	-	-	-	-	-
01/06/2018		ID1041	Niraparib	Ovarian cancer	25	25	25	25	25	25
28/06/2018		ID925	Alectinib	Lung cancer	**	2	2	2	2	2

*Powys and Abertawe Bro Morgannwg also commission cancer services from other cancer providers. These dates relate to the Powys and Abertawe Bro Morgannwg populations that Velindre Cancer Centre are commissioned for and there may be variability with dates from other cancer service providers. ** Cardiff and Vale UHB have their own lung service.

Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[']' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 30 June 2018.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 30 June 2018.
		Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 30 June 2018. '-' indicates CAA is not yet available.